What to Do If Your GLP-1 Telehealth Provider Shuts Down

The FDA's 2026 enforcement wave isn't hypothetical — 30 warning letters, a DOJ referral for Hims & Hers, and proposed rules to restrict compounding APIs. Some GLP-1 telehealth companies will shut down, restructure, or stop offering compounded products. If your platform disappears, what happens to your medication?

Why Providers Are at Risk

The GLP-1 telehealth market grew explosively during the 2022–2024 drug shortages, when compounding pharmacies were legally permitted to produce semaglutide and tirzepatide copies. As shortages have resolved for some formulations, the legal basis for certain compounding operations has narrowed. The FDA has signaled through warning letters, public statements, and proposed rulemaking that it intends to restrict mass-market compounding of GLP-1 products.

Companies most at risk are those that received FDA warning letters and haven't corrected violations, companies relying on 503B outsourcing facilities that may lose the ability to compound GLP-1 APIs under proposed rules, platforms with thin clinical operations layered on top of marketing-heavy business models, and newer entrants without the financial reserves to weather a regulatory transition.

This doesn't mean all GLP-1 telehealth will disappear. Patient-specific compounding under 503A remains legal. Platforms offering brand-name FDA-approved medications are unaffected. But specific companies — especially those the FDA has already flagged — may not survive the current regulatory environment.

Immediate Steps If Your Provider Closes

Don't panic — but don't wait. GLP-1 medications should not be stopped abruptly without clinical guidance. While there's no dangerous withdrawal syndrome (unlike some other medications), stopping suddenly can cause rebound weight gain and metabolic changes. Your priority is continuity of care.

Assess your current supply. How many weeks of medication do you have left? If you have 4+ weeks, you have time to transition. If you have less than 2 weeks, move quickly.

Download your medical records. Before your platform's website goes offline, download or screenshot your consultation notes, prescription history, lab results, and any clinical correspondence. You'll need these when onboarding with a new provider. Under HIPAA, you have the right to request your medical records from any provider — do so in writing immediately if the company is winding down.

Contact your credit card company. If you've prepaid for future months that won't be delivered, initiate a chargeback or dispute. Time limits apply — typically 60–120 days from the charge date depending on your card issuer.

Finding a New Provider Quickly

When you're switching under time pressure, focus on three things: a platform that accepts existing patients at their current dose (no forced re-titration from scratch), a platform with fast onboarding (same-week consultation), and a platform with demonstrated stability (operating for 1+ years, no FDA warning letters).

Tell the new platform during intake that you're transferring from another provider and specify your current medication, dose, and how long you've been on it. Responsible platforms will continue your current dose without an unnecessary restart. Upload your previous lab work and medical records during enrollment to expedite the process.

Bridging the Gap

If there's a gap between your last dose from the old provider and your first shipment from the new one, your options are limited but real:

Your primary care doctor. If you have a PCP, call them and explain the situation. They can write a bridge prescription for brand-name GLP-1 (Wegovy, Ozempic, Zepbound) to be filled at a retail pharmacy while your telehealth transition completes. You'll pay retail unless you have insurance coverage, but a one-month bridge is better than going cold turkey.

Urgent care or walk-in clinic. Some urgent care providers will write short-term bridge prescriptions for medications you're already taking. Bring documentation of your current prescription.

Manufacturer savings programs. If you need brand-name medication as a bridge, Novo Nordisk and Eli Lilly's current savings programs can reduce the cost significantly — Wegovy starting at $199/month, Zepbound starting at $399/month.

Stable Platforms for Transfer